Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Acute rhinosinusitis in adults.

BIBLIOGRAPHIC SOURCE(S)

  • University of Michigan Health System. Acute rhinosinusitis in adults. Ann Arbor (MI): University of Michigan Health System; 2007 Mar. 8 p. [6 references]

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: University of Michigan Health System. Acute rhinosinusitis in adults. Ann Arbor (MI): University of Michigan Health System; 2005 Feb. 8 p.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Note from National Guideline Clearinghouse (NGC): The following key points summarize the content of the guideline. Refer to the full text for additional information, including detailed information on best predictors of rhinosinusitis, preferred treatment regimens, and dosing and cost considerations for first and second trial antibiotic treatments.

The levels of evidence [A-D] are defined at the end of the "Major Recommendations" field.

Definitions

Acute rhinosinusitis is an inflammation of the paranasal sinuses and the nasal cavity lasting no longer than 4 weeks. It can range from acute viral rhinitis (the common cold) to acute bacterial rhinosinusitis. Fewer than 5 in 1,000 colds are followed by bacterial rhinosinusitis.

Diagnosis

Estimate the probability of acute bacterial rhinosinusitis based on history and physical examination. The best predictors include maxillary toothache, poor response to decongestants, patient report of colored nasal discharge, purulent secretions by exam, and abnormal transillumination.

Treatment

Prescribe antibiotic therapy based on benefits and risks. Benefits depend on the probability of bacterial infection and the severity of symptoms. Risks of antibiotics include allergic reaction, potential side effects, and promotion of bacterial resistance. Antibiotics have not been shown to decrease the risk of complication or progression to chronic rhinosinusitis. Symptoms resolve within two weeks without antibiotics in 70% of cases and with antibiotics in 85% of cases.

First line antibiotics for acute bacterial rhinosinusitis are amoxicillin and trimethoprim/sulfamethoxazole. They are superior to placebo and as effective as other agents that are more expensive, have greater risk of side effects, and/or should be reserved for more serious infections [A]. Use first-line alternatives (e.g., doxycycline, azithromycin) only for patients allergic to both first line drugs. The usual initial course of antibiotics should be 10 to 14 days. An exception is azithromycin (500 mg daily), which should be prescribed for 3 days.

For partial but incomplete resolution after an initial course of antibiotics, extend the duration of antibiotic therapy by an additional 7 to 10 days for a total of 3 weeks of antibiotics.

For minimal or no improvement with initial treatment, consider changing to an antibiotic with broader coverage, including resistant strains. Options include amoxicillin at high dose, amoxicillin/clavulanate, and levofloxacin. Avoid ciprofloxacin due to limited activity against Streptococcus pneumoniae. Do not use telithromycin because risks for hepatotoxicity, loss of consciousness, and visual disturbances appear to outweigh potential benefits for this indication.

Ancillary therapies for acute rhinosinusitis have little supporting data. Some studies examining treatments for viral upper respiratory infections have shown:

  • Efficacy in symptom control: decongestants and anticholinergics, including "first-generation" antihistamines (diphenhydramine, chlorpheniramine, clemastine) [A].
  • Possible efficacy: zinc gluconate lozenges, vitamin C, Echinacea extract, saline irrigation [conflicting or insufficient data].
  • No significant benefit: guaifenesin (except possibly at high dose), saline spray, steam, "non-sedating" antihistamines (loratadine, fexofenadine, cetirizine).

For recurrent acute rhinosinusitis or acute rhinosinusitis superimposed on chronic rhinosinusitis, the addition of high dose nasal corticosteroids may decrease duration of symptoms and improve rate of clinical success [A]. However, this approach is inconvenient, has potential side effects, and significant cost.

Imaging

If symptoms of rhinosinusitis persist for more than three weeks despite antibiotics or recur more than three times per year, a sinus computed tomography (CT) scan should be performed while the patient is symptomatic to reassess diagnosis and determine need for referral [C, D]. CT scans provide much better definition than a plain sinus x-ray series. Plain sinus x-rays, therefore, are not recommended.

  • New low dose CT scanners are becoming available with the advantage of radiation exposure of about 10% to 15% of a full sinus CT scan.
  • A limited (coronal plan only) sinus CT scan provides excellent imaging detail with only 50% of the radiation exposure of a full (axial and coronal planes) sinus CT scan.
  • At University of Michigan Health System the charge is $1,416 for any sinus CT scan (low dose, limited, or full).

Definitions:

Levels of evidence for the most significant recommendations:

  1. Randomized controlled trials
  2. Controlled trials, no randomization
  3. Observational trials
  4. Opinion of expert panel

CLINICAL ALGORITHM(S)

An algorithm is provided in the original guideline document for the diagnosis of acute bacterial rhinosinusitis.

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

When possible, conclusions were based on prospective randomized clinical trials. In the absence of randomized controlled trials, observational studies were considered. If none were available, expert opinion was used.

The type of evidence is identified and graded for the most significant recommendations (see "Major Recommendations").

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • University of Michigan Health System. Acute rhinosinusitis in adults. Ann Arbor (MI): University of Michigan Health System; 2007 Mar. 8 p. [6 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

1996 May (revised 2007 Mar)

GUIDELINE DEVELOPER(S)

University of Michigan Health System - Academic Institution

SOURCE(S) OF FUNDING

University of Michigan Health System

GUIDELINE COMMITTEE

Rhinosinusitis Guideline Team

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Team Leader: Jane T. McCort, MD, General Internal Medicine

Team Members: R. Van Harrison, PhD, Medical Education; James F. Peggs, MD, Family Medicine; Jeffrey E. Terrell, MD, Otolaryngology

Guidelines Oversight Team: Connie J. Standiford, MD; Lee A. Green, MD, MPH; R. Van Harrison, PhD

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

The University of Michigan Health System endorses the Guidelines of the Association of American Medical Colleges and the Standards of the Accreditation Council for Continuing Medical Education that the individuals who present educational activities disclose significant relationships with commercial companies whose products or services are discussed.  Disclosure of a relationship is not intended to suggest bias in the information presented, but is made to provide readers with information that might be of potential importance to their evaluation of the information.

Team Member; Company; Relationship:

Jane T. McCort, MD (none)

R. Van Harrison, PhD (none)

James F. Peggs, MD (none)

Jeffrey E. Terrell, MD, Pfizer, Speaker

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: University of Michigan Health System. Acute rhinosinusitis in adults. Ann Arbor (MI): University of Michigan Health System; 2005 Feb. 8 p.

GUIDELINE AVAILABILITY

AVAILABILITY OF COMPANION DOCUMENTS

PATIENT RESOURCES

None available

NGC STATUS

This summary was completed by ECRI on August 21, 2000. The information was verified by the guideline developer on November 22, 2000. This NGC summary was updated on May 16, 2005. The updated information was verified by the guideline developer on May 20, 2005. This summary was updated by ECRI on January 27, 2006 following the U.S. Food and Drug Administration (FDA) advisory on Ketek (telithromycin). This summary was updated by ECRI on July 3, 2006 following the updated U.S. Food and Drug Administration (FDA) advisory on Ketek (telithromycin). This summary was updated by ECRI on March 6, 2007 following the updated FDA advisory on Ketek (telithromycin). This summary was updated by ECRI Institute on July 31, 2008. The updated information was verified by the guideline developer on August 15, 2008.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is copyrighted by the University of Michigan Health System (UMHS).

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo